ATAlyna Turner

Alyna Turner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alyna Turner has a total of 299 co-authors. Here are the top co-authors by number of shared publications:

  • Michael Berk

    Deakin Institute for Mental and Physical Health and Clinical Translation (Deakin IMPACT), School of Medicine, Deakin University and Barwon Health, Geelong, Australia

    21 shared publications
  • Olivia May Dean

    Institute for Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Deakin University, Geelong, VIC, Australia

    14 shared publications
  • Anna L. Wrobel

    IMPACT – The Institute for Mental and Physical Health and Clinical Translation, School of Medicine Deakin University Geelong Victoria Australia

    11 shared publications
  • Olivia M. Dean

    Deakin University, School of Medicine, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, Geelong, Victoria, Australia; Florey Institute for Neuroscience and Mental Health, University of Melbourne, Victoria, Australia

    11 shared publications
  • Melanie Maree Ashton

    Deakin University, IMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, VIC, Australia

    9 shared publications
  • Bianca E. Kavanagh

    Affiliations Deakin University, Deakin Rural Health, School of Medicine, Warrnambool, Victoria, Australia, Brophy Family and Youth Services, Warrnambool, Victoria, Australia

    8 shared publications

Latest Publications

  • Open Access

    The bidirectional predictive association between methamphetamine use and depression

    by Lucy T. Tran, Philip J. Clare, Louisa Degenhardt, Dan I. Lubman, Michael Berk, Gregory Carter, Shalini Arunogiri, Alyna Turner, Olivia M. Dean, Peter Kelly, et al.

    Background and aims: Co‐occurrence of methamphetamine dependence and depression is high, though the direction of this temporal relationship is unclear. We investigated the direction of the temporal relationship between methamphetamine use and depression. Design: A longitudinal random‐intercept cross‐lagged panel model analysis was conducted using 12 contiguous weeks of data from a randomised controlled trial (ACTRN12618000366257). Setting: Melbourne, Geelong and Wollongong, Australia. Participants: 153 adult participants dependent on methamphetamine. Measurements: Each week, days of methamphetamine use in the past week were assessed using the Timeline Followback, and clinically significant symptoms of depression were defined as a score of 4 or greater on the Brief Psychiatric Rating Scale depression item. Results: Relative to their average, if an individual increased their methamphetamine use in one week, their probability of experiencing clinically significant depressive symptoms increased the following week [estimate = 0.271, 95% confidence interval (CI) = 0.177–0.365, P < 0.001]. Additionally, if an individual's probability of experiencing clinically significant depressive symptoms increased in one week above their average, their subsequent week's methamphetamine use increased (estimate = 0.414, 95% CI = 0.291–0.537, P < 0.001). Summary: There appears to be evidence of a bidirectional relationship between days of methamphetamine use and clinically significant depressive symptoms within a weekly timeframe.

  • Open Access

    Effectiveness of a Brief Internet-Based Workplace Training Program to Support Help Seeking for Mental Ill-Health: Cluster Randomized Controlled Trial

    by Philip J Batterham, Amelia Gulliver, Cassandra Heffernan, Alison L Calear, Aliza Werner-Seidler, Alyna Turner, Louise M Farrer, Mary Lou Chatterton, Cathrine Mihalopoulos, Monica Gendi, et al.

    Background: Depression and anxiety are prevalent in working-aged adults. Although treatment provided by health professionals can improve symptoms and functioning, many people experiencing mental ill-health do not seek help. There have been very few effective interventions to improve help seeking in adults, with none implemented across diverse workplaces through online delivery. Objective: The primary aim of this trial was to test the effectiveness of a co-designed program for increasing professional help seeking intentions in Australian employees, relative to an active control condition. Methods: A triple-blinded, 2-arm cluster randomized controlled trial (N=487; control workplaces: n=26 and intervention workplaces: n=25) was conducted to assess the relative effectiveness of Helipad, a fully automated co-designed single-session interactive program (intervention condition) with a standard psychoeducation program (active control condition). Eligible workplaces (those with ≥50 employees and an employee assistance program; clusters) were recruited via advertising or invited directly by researchers. Eligible participants (employees in a participating Australian workplace, aged ≥18 y, living in Australia, fluent in reading and understanding English, and had access to a device and a reliable internet connection) completed a pretest, immediate posttest, and 6-month follow-up survey sent via email assessing help seeking intentions (primary outcome); mental illness stigma; mental health literacy; help seeking attitudes and behavior; work and activity functioning; quality of life; and symptoms of depression, anxiety, and general psychological distress. Results: A significant difference in change over time in professional help seeking intentions was found between the 2 conditions ( F 2,185.44 =6.89; P =.001), with planned contrasts showing that the Helipad program was effective in increasing professional help seeking intentions compared with the control at the primary end point of immediate posttest ( t 359.35 =−3.72; P <.001). This difference was not maintained at the 6-month follow-up ( t 119.76 =−1.05; P =.30). Retention rates were 71.1% at posttest and 24.9% at follow-up. The Helipad program was also associated with improved mental health literacy and help seeking attitudes at posttest. Helipad was not significantly superior to the control in reducing mental illness stigma or improving professional help seeking behavior; functioning; quality of life; or symptoms of depression, anxiety, or general psychological distress (secondary outcomes) at the 6-month follow-up. A total of 15 people (control: n=9, 4.5%; intervention: n=6, 4.3%) reported adverse events at posttest. Conclusions: This study demonstrated that the co-designed online Helipad program was effective in improving the intentions of employees to seek help from a professional compared to an active control. The program also improved mental health literacy and help seeking attitudes, but these changes were not sustained and did not translate into observable differences in help seeking behaviors or mental health symptoms. This was the first trial of a co-designed intervention to improve mental health help seeking in general workplaces, with previous trials focusing primarily on specific high-risk work environments. Workplace programs that can be delivered at scale may lead to more appropriate engagement with professional mental health care to prevent poor mental health outcomes and increase productivity.


  • The Candesartan Adjunctive Depression Trials—CADET

    by Melanie M. Ashton, Chun Hui J. Park, Brisa S. Fernandes, Judy Hope, Chee H. Ng, Malcolm Hopwood, Jon-Paul Mbbs Khoo, Gin S. Malhi, Stella May Gwini, John Mbbs Amerena, et al.

    Background: Depression in both bipolar and major depressive disorder remains a major unmet need due to treatment resistance to the existing treatments. Emerging evidence implicates the renin-angiotensin system in regulating the cellular stress response relevant to depression, suggesting it as a novel therapeutic target for depression. Candesartan, a common hypertension medication, decreases neuroinflammation, oxidative and nitrosative pathway activation, and neurotrophic signalling of angiotensin II by predominantly blocking the angiotensin II type 1 receptors (AT1R). Given AT1R-induced activities are implicated in the pathophysiology of bipolar and major depressive disorder and with supportive pharmacoepidemiology data, candesartan may represent a novel antidepressant strategy. Methods: The CADET Trials are 2 parallel 16-week double-blind randomized placebo-controlled trials of adjunctive candesartan (or placebo) for the treatment of bipolar depression (CADET-BD) and major depressive disorder (CADET-UD). Each trial aims to recruit 240 adult participants. The primary outcome is the between-group (ie, intervention vs. placebo) differential change from baseline to week 16 in depression symptoms as measured by the Montgomery Åsberg Depression Rating Scale. Secondary outcomes measure depression, mania, anxiety, quality of life, cost-effectiveness, functioning, substance use, cognition, and biological markers. Findings: Findings are not yet available as the trial is ongoing. Implications: The CADET Trials examine the efficacy of candesartan in reducing depressive symptoms in both unipolar and bipolar depression, and whether its effects are mediated through the renin-angiotensin system. Candesartan is affordable, accessible, and well-tolerated. If effective, it could quickly be adopted into clinical practice as a new adjunctive medication for the treatment of these disorders.


  • Open Access

    Potential Impact of Childhood Abuse on Quality of Life During Mood‐Stabilising Treatment in Individuals Living With Bipolar Disorder

    by Anna L. Wrobel, Olivia M. Dean, Mojtaba Lotfaliany, Michael Berk, Louisa G. Sylvia, Michael E. Thase, Thilo Deckersbach, Mauricio Tohen, Melvin G. McInnis, James H. Kocsis, et al.

    Background: There is a lack of research examining whether childhood abuse affects the quality of life (QoL) of individuals living with bipolar disorder and its improvement over the course of treatment. Methods: Data from the Clinical Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder were used to explore the associations between childhood abuse and multiple domains of QoL among 476 outpatients with bipolar disorder. Rates of change in QoL throughout treatment were explored with a series of Generalised Estimation Equations for repeated measures. Results: At baseline, childhood abuse was related to poorer QoL in the domains of subjective feelings of wellbeing, social relationships and general activities—but not in physical health or leisure activities. Throughout treatment, participants with a history of childhood abuse reported significantly worse QoL in the same domains, than participants with no history of childhood abuse. Interestingly, exploratory analyses showed that participants with a history of childhood abuse and a current diagnosis of post‐traumatic stress disorder (PTSD) had significantly worse QoL in all domains, than participants with no history of childhood abuse or diagnosis of PTSD. There were no significant differences between groups in change in QoL in any of the domains. Conclusion: This study comprehensively investigated the relationships between a history of childhood abuse and QoL among people with bipolar disorder who were receiving pharmacotherapy. Although the present findings need to be replicated, they suggest significant impairment in several domains of QoL associated with childhood abuse, which has service and treatment implications for trauma‐informed care. Trial Registration: ClinicalTrials.gov identifier: NCT01331304

  • Open Access

    Adverse childhood experiences and cardiometabolic risk factors in people with bipolar disorder

    by Alyna Turner, Maya Kuperberg, Hugh McGovern, Anna Wrobel, Olivia M. Dean, Michael Berk, Louisa Sylvia, Susan L. McElroy, Mauricio Tohen, Richard C. Shelton, et al.


  • Open Access

    Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder

    by Ramisha Khan, Alyna Turner, Michael Berk, Ken Walder, Susan Rossell, Alexandre A. Guerin, Jee Hyun Kim

    Methamphetamine use disorder is a pressing global health issue, often accompanied by significant cognitive deficits that impair daily functioning and quality of life and complicate treatment. Emerging evidence highlights the potential role of genetic factors in methamphetamine use disorder, particularly in association with cognitive function. This review examines the key genetic and cognitive dimensions and their interplay in methamphetamine use disorder. There is converging evidence from several studies that genetic polymorphisms in BDNF, FAAH, SLC18A1, and SLC18A2 are associated with protection against or susceptibility to the disorder. In addition, people with methamphetamine use disorder consistently displayed impairments in cognitive flexibility and inhibitory control compared with people without the disorder. These cognitive domains were associated with reactivity to methamphetamine cues that were positively correlated with total years of methamphetamine use history. Emerging research also suggests that inhibitory control is negatively correlated with lower blood FAAH mRNA levels, while cognitive flexibility positively correlates with higher blood SLC18A2 mRNA levels, highlighting how genetic and cognitive dimensions interact in methamphetamine use disorder. We also include some future directions, emphasizing potential personalized therapeutic strategies that integrate genetic and cognitive insights. By drawing attention to the interplay between genes and cognition, we hope to advance our understanding of methamphetamine use disorder and inform the development of targeted interventions.


  • Open Access

    Pharmacotherapy in Comorbid Bipolar Disorder and Post‐Traumatic Stress Disorder From the STEP‐BD Cohort

    by Samantha E. Russell, Anna L. Wrobel, David R. Skvarc, Mojtaba Lotfaliany, Olivia M. Dean, Melanie M. Ashton, Pedro V. S. Magalhães, Andrew Nierenberg, Michael Berk, Alyna Turner

    Introduction: Post‐traumatic stress disorder (PTSD) is more prevalent in those with bipolar disorder (BD) than in the general population, with rates of PTSD as high as 55% in some BD cohorts. Despite this, little research explores the effects of pharmacotherapy treatments in those with comorbid BD and PTSD. This study aims to explore patterns of pharmacotherapy use at baseline and their impact on symptoms in individuals with BD alone and comorbid BD and PTSD.Methods: The Systematic Treatment Enhancement Program for BD (STEP‐BD) cohort was utilised to examine and compare BD symptoms and pharmacotherapy treatments between those with BD alone (n = 3393) and those with comorbid BD and PTSD (n = 304). We conducted regression models to compare those with and without comorbid PTSD. Models included measures of depression, mania, functioning and quality of life over 24 months of the STEP‐BD study. We included baseline pharmacotherapies (lithium, valproate, antidepressants, antipsychotics and benzodiazepines) as predictor outcome variables in all models.Results: At baseline, reported use of lithium was lower in the comorbid BD and PTSD group, while the use of antidepressants, antipsychotics and benzodiazepines was significantly higher in the comorbid BD and PTSD than in the BD alone group. Benzodiazepine use was associated with a small improvement in depression symptom scores and poorer quality of life in those with comorbid BD and PTSD. Lastly, those with comorbid PTSD experienced higher levels of mania and depression symptoms and lower functioning and quality of life compared to BD alone, irrespective of pharmacotherapy treatment.Conclusion: Clinical trial participants with BD and PTSD reported worse symptoms and outcomes across 24 months of the STEP‐BD study compared to those without comorbid PTSD, regardless of baseline medication use. These results highlight the importance of considering comorbidity in the treatment of mental health conditions, specifically BD, and the need for further exploration of effective treatment options.

  • Open Access

    Understanding the relationship between childhood abuse and affective symptoms in bipolar disorder: New insights from a network analysis

    by Anna L. Wrobel, Megan Turner, Olivia M. Dean, Michael Berk, Louisa G. Sylvia, Michael E. Thase, Thilo Deckersbach, Mauricio Tohen, Melvin G. McInnis, James H. Kocsis, et al.


  • Open Access

    A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: A study protocol for the Tina Trial

    by Rebecca McKetin, Tayla Degan, Lucy Saunders, Long Nguyen, Gregory Dore, Steven Shoptaw, Michael Farrell, Louisa Degenhardt, Peter J Kelly, Alyna Turner, et al.

    Background There are no approved pharmacotherapies for methamphetamine use disorder. Two preliminary phase 2 randomised controlled trials have found mirtazapine, a tetracyclic antidepressant, to be effective in reducing methamphetamine use. The proposed Tina Trial is the first phase 3 placebo controlled randomised trial to examine the effectiveness and safety of mirtazapine as an outpatient pharmacotherapy for methamphetamine use disorder. Methods This is a multi-site phase 3 randomised, double-blind, placebo-controlled parallel trial. Participants are randomly allocated (1:1) to receive either mirtazapine (30 mg/day for 12 weeks) or matched placebo, delivered as a take-home medication. The target population is 340 people aged 18–65 years who have moderate to severe methamphetamine use disorder. The trial is being conducted through outpatient alcohol and other drug treatment clinics in Australia. The primary outcome is measured as self-reported days of methamphetamine use in the past 4 weeks at week 12. Secondary outcomes are methamphetamine negative oral fluid samples, depressive symptoms, sleep quality, HIV risk behaviour and quality of life. Other outcomes include safety (adverse events), tolerability, and health service use. Medication adherence is being monitored using MEMS® Smart Caps fitted to medication bottles. Discussion This trial will provide information on the safety and effectiveness of mirtazapine as a pharmacotherapy for methamphetamine use disorder when delivered as an outpatient medication in routine clinical practice. If found to be safe and effective, this trial will support an application for methamphetamine use disorder to be included as a therapeutic indication for the prescription of mirtazapine. Trial Registration: Australian and New Zealand Clinical Trials Registry (ACTRN12622000235707). Registered on February 9, 2022.

  • Open Access

    Non-pharmacological interventions to improve mental health outcomes among female carers of people living with a neurological condition: a systematic review

    by A. M. J. Denham, K. Haracz, M. L. Bird, B. Bonevski, N. J. Spratt, A. Turner, W. Z. Chow, M. Larkin, N. Mabotuwana, H. Janssen

    This systematic review aims to examine the effectiveness of non-pharmacological interventions for improving mental health outcomes among female carers of people living with a neurological condition. A narrative synthesis of English-language randomized controlled trials was undertaken. 18 unique studies were included. Intervention components that were found to have improved mental health outcomes were: delivered in person, to groups, on an intermittent schedule with ≥10 sessions; had a duration between 3-6 months; and were facilitated by research staff or allied health professionals. As the review had few robust studies, results of mental health outcomes reported in studies assessed as low risk of bias were highlighted in the review. Psychoeducation interventions, cognitive behavioural interventions, and support group interventions were found to improve depression. Psychoeducation interventions were also found to improve burden. There is a clear need for adequately powered, high-quality randomised controlled trials to determine the effectiveness of non-pharmacological interventions for female carers of people living with a neurological condition.